Scribe Therapeutics SCTX

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies to extend healthy lifespan through disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic diseases, developing genetic medicines designed to be well-tolerated, effective, durable, and scalable enough to shift treatment from symptom-driven intervention to population-level prevention. Its lead product candidate, STX-1150, utilizes the proprietary ELXR technology to deliver persistent LDL-C reduction without permanent genetic changes, targeting atherosclerotic cardiovascular disease.

Scribe Therapeutics, Inc. generates revenue primarily through upfront payments, milestone payments, expense reimbursements, and royalties from strategic collaborations with leading biopharmaceutical companies. The company also seeks to commercialize its wholly-owned pipeline of product candidates, including STX-1150, STX-1200, and STX-1400, which target key lipid drivers of atherosclerotic cardiovascular disease. Revenue is derived from licensing its CRISPR-based technologies, ELXR and XE, to partners such as Sanofi and Lilly for development in areas including sickle cell disease and neurological disorders.

The company operates through the following segments:

• STX-1150: This segment focuses on the development of STX-1150, an epigenetic silencing therapy based on the ELXR technology designed to durably lower LDL-C by repressing PCSK9 expression. The product candidate utilizes lipid nanoparticle delivery of mRNA encoding the ELXR molecule and a PCSK9-targeting guide RNA. STX-1150 aims to provide persistent LDL-C reduction for years to decades without altering the underlying DNA sequence, offering a potential alternative to chronic therapies.
• STX-1200: This segment develops STX-1200, a gene-editing therapy based on the XE technology targeting the LPA gene to reduce elevated lipoprotein(a) levels. The approach uses lipid nanoparticle delivery to precisely edit and inactivate the LPA gene in hepatocytes, aiming for a durable, one-time treatment. STX-1200 is designed to address a significant unmet need in patients with genetically driven high Lp(a), a strong independent risk factor for atherosclerotic cardiovascular disease.
• STX-1400: This segment advances STX-1400, a gene-editing therapy based on the XE technology targeting the APOC3 gene to reduce triglyceride levels and lower cardiovascular risk. The product candidate uses lipid nanoparticle delivery to edit the APOC3 gene in hepatocytes, aiming to increase clearance of triglyceride-rich lipoproteins. STX-1400 is intended to provide a durable solution for patients with severe hypertriglyceridemia and related conditions such as familial chylomicronemia syndrome.

Scribe Therapeutics, Inc. is positioned as an innovator in the genetic medicine space, leveraging its proprietary CRISPR by Design approach to engineer two distinct technologies—ELXR for epigenetic silencing and XE for gene editing—derived from the novel CasX enzyme. This differentiation provides competitive advantages over Cas9-based platforms, including improved specificity, delivery flexibility, and a broader therapeutic window. The company faces competition from established gene editing firms such as CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Verve Therapeutics, as well as companies developing epigenetic modulation and RNAi-based therapies.

Scribe Therapeutics, Inc. serves patients with cardiovascular and metabolic diseases, particularly those with elevated LDL-C, lipoprotein(a), and triglycerides who are at risk for atherosclerotic cardiovascular disease. The company also collaborates with biopharmaceutical partners such as Sanofi and Lilly to develop therapies for sickle cell disease and neurological and neuromuscular disorders, expanding its impact beyond its core focus.